English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The direct and beta adrenergic blocking effect of M& B 17, 803A was investigated in the isolated supported dog heart preparation (ISHP) in the presence of a constant coronary blood flow. Administration of graded doses of norepinephrine into the coronary arteries produced a dose-dependent increase in the heart rate, myocardial contractile force, left ventricular systolic pressure and coronary artery perfusion pressure. The myocardial oxygen consumption was increased significantly (p<0.05) by each dose of norepinephrine. Pretreatment of the ISHP with 0.3mg/Kg of M & B 17, 803A produced a generalized myocardial depression and an increase in coronary artery perfusion pressure, whereas the smaller dose (0.15mg/Kg) of the blocking agent was without any effect. Both the doses of M & B 17, 803A produced a competitive blockade of the effect of norepinephrine on the myocardial hemodynamics and oxygen consumption. M&B 17, 803A thus appears to be a potent agent that blocks the beta receptors, and has a significant myocardial depressant activity.

japanese heart journal

Cardiovascular Effects of dl-1-(2-Acetyl-4-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane (M &amp; B 17, 803A), a New Cardioselective Beta Adrenoreceptor Blocking Agent